The OPTION trial found that left atrial appendage (LAA) closure after ablation for atrial fibrillation (AF) provides long-term protection against thromboembolism equivalent to oral anticoagulants, with a lower risk of bleeding. The study, conducted at 106 sites in 10 countries, included 1600 patients with AF and compared outcomes of LAA closure with oral anticoagulants. Results showed that LAA closure was noninferior to anticoagulants in preventing death, stroke, and systemic embolism. The study’s findings suggest that LAA closure is an effective first-line option for stroke prevention after ablation for AF, especially in patients with heart failure.
Source link
For AF, LAA Rivals Anticoagulants After Ablation
